|Over a month ago|
JPMorgan downgrades Kala Pharmaceuticals on slower than expected Eysuvis launch » 09:5308/0608/06/21
JPMorgan analyst Christopher Neyor downgraded Kala Pharmaceuticals to Neutral from Overweight after the company reported lower-than-expected Q2 revenue drive largely by an Eysuvis sales miss. His core thesis has centered on the early-stage Eysuvis product launch in acute dry eye disease, but he now expects a more gradual Eysuvis launch given initial launch trends have progressed slower than expected, Neyor tells investors.
Kala Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright » 06:3408/0608/06/21
H.C. Wainwright analyst…
H.C. Wainwright analyst Yi Chen lowered the firm's price target on Kala Pharmaceuticals to $11 from $14 and reiterates a Buy rating on the shares post the Q2 results.
Kala Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan » 06:2808/0608/06/21
JPMorgan analyst Christopher Neyor downgraded Kala Pharmaceuticals to Neutral from Overweight.
Kala Pharmaceuticals sees cash funding operations for at least two years » 07:2208/0508/05/21
As of June 30, 2021, Kala…
As of June 30, 2021, Kala had cash, cash equivalents and short-term investments of $149.6 million, compared to $153.5 million as of December 31, 2020. This decrease primarily reflects cash used in operations, largely offset by net proceeds of $40.7 million received from sales of common stock under Kala's at-the-market offering program in the six months ended June 30, 2021, and the release of $10 million in restricted cash in connection with Kala's repayment of its credit facility with Athyrium following its entry into a loan agreement with Oxford Finance. Kala anticipates that its cash resources as of June 30, 2021, together with anticipated revenue from EYSUVIS and INVELTYS, will enable it to fund its operations for at least two years.
Kala Pharmaceuticals reports Q2 EPS (57c), consensus (45c) » 07:2208/0508/05/21
Reports Q2 revenues…
Reports Q2 revenues $3.1M, consensus $5.33M. "In recent months, we have made substantial progress toward establishing EYSUVIS as the preferred prescription therapy for the short-term treatment of dry eye disease, expanding market access with Commercial and Medicare Part D health plans and strengthening our base of prescribing eye care professionals," said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. "We are encouraged by the very positive feedback we consistently receive from physicians and patients, who describe EYSUVIS as an effective and comfortable medicine, and look forward to building on this foundation as we continue with the EYSUVIS launch. In parallel, we continue to promote INVELTYS and are advancing our pipeline of new chemical entities for front and back of the eye diseases, as we work to build a robust and sustainable portfolio of innovative treatments."
|Over a quarter ago|
Kala Pharmaceuticals announces Eysuvis now covered by OptumRx » 07:0306/0306/03/21
Kala Pharmaceuticals announced that OptumRx, one of the largest pharmacy benefit managers, or PBM, in the United States, has added Eysuvis 0.25% as a covered brand on its commercial formularies, effective May 21.
Kala Pharmaceuticals price target lowered to $14 from $16 at H.C. Wainwright » 06:1905/0605/06/21
H.C. Wainwright analyst…
H.C. Wainwright analyst Yi Chen lowered the firm's price target on Kala Pharmaceuticals to $14 from $16 and reiterates a Buy rating on the shares following the Q1 results.
Kala Pharmaceuticals reports Q1 EPS (49c), consensus (68c) » 07:3905/0505/05/21
"We are early in the…
"We are early in the launch of EYSUVIS and encouraged by our progress to establish the product as the first and only prescription therapy specifically for the short-term treatment of dry eye disease. We have secured market access for approximately 43 percent of all commercial lives and are pleased with the early launch metrics and feedback from eye care professionals who view EYSUVIS as a first-line treatment option for a range of patients suffering from dry eye flares," said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. "The new credit facility announced today helps extend our projected cash runway to at least two years, strengthening our financial position to invest across our business as we build on early EYSUVIS momentum, continue to promote INVELTYS and advance our pipeline of new chemical entities targeted to address front and back of the eye diseases." Non-GAAP net loss was $25.2 million for the quarter ended March 31, 2021, compared to $19.0 million for the same period in 2020. The weighted average number of shares used to calculate net loss per share was 61.7 million for the quarter ended March 31, 2021, and 40.8 million for the quarter ended March 31, 2020.
Kala Pharmaceuticals participates in a webinar with Northland » 12:5004/2904/29/21
Webinar with Key Opinion…
Webinar with Key Opinion Leader Dr. Lisa Nijm and KALA Pharmaceuticals management will be held on April 29 at 1 pm. Webcast Link
Kala Pharmaceuticals participates in a conference call hosted by Northland » 12:2504/2904/29/21
Northland holds a Key…
Northland holds a Key Opinion Leader call with Dr. Lisa Nijm on April 29 at 1 pm. Reference Link